U.S. District Court Enters Judgment of No Infringement of Patent Asserted Against Kurin Inc. by Magnolia Medical Technologies, Inc.

Kurin Inc., the inventor and manufacturer of Kurin^® blood culture collection sets, announced that the U.S. District Court for the District of Delaware has entered a judgment that Kurin does not infringe U.S. Patent No. 9,855,001 in the patent-infringement lawsuit Magnolia brought against Kurin.  Magnolia earlier withdrew two other patents from the case, leaving just one of the four originally asserted patents for the upcoming trial.

“The fact that Magnolia has finally agreed to entry of a judgment of no infringement of this patent confirms yet again our longstanding belief that Magnolia’s case lacks merit,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock. “As we said years ago when they filed this suit, we think Magnolia’s lawsuit reflects a belief that it cannot compete in the marketplace on the merits of its product. We look forward to defending ourselves against the last remaining patent in the upcoming trial.”

Rogers added “Kurin has quietly become the market leader by providing a simple, low cost and easy to use solution that customers prefer over other options, including Magnolia’s Steripath device.”

Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection in contrast to conventional diversion.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.